The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that the heavy phase of a major undertaking is substantially done, and the collecting phase has begun but is early in the numbers. The transcript is from EVgo Q2 2022 earnings call. Key points: They are building out charging network. They mention placing stalls, construction pipeline, partnerships. They talk about "EVgo eXtend" model where they get cash flow immediately because customer incurs capital expenditures. They also mention that they have been preparing for NEVI program, but that's future. They mention "we have already eclipsed the number of stalls we placed into operation in all of 2021" for first half of 2022. They talk about "operational stall growth has picked up pace year-to-date." They mention "some challenges remain on the utility side where we're still experiencing energization delays" but affirm guidance. They talk about "we are affirming our 2022 operational and financial guidance." They talk about "we have not disclosed the terms of this deal" for Pilot. They talk about "the cash flow profile of our core, developed owned operate model versus a new eXtend model." For eXtend, they see positive cash flow immediately because customer incurs CapEx. But that's a new model, not necessarily a completed heavy phase. The question asks: Does management convey that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where the company collects on that completed work, with reported results still mostly reflecting the paying phase rather than the collecting phase? We need to see if management describes a heavy phase as substantially done. They talk about building out network, but they are still in the middle of expansion. They have a pipeline of 3,669 stalls, and they are constructing. They affirm guidance for 3,000-3,300 stalls by end of 2022. They are still spending CapEx heavily ($44M in Q2). They are still in the middle of the build-out. They mention "we have already eclipsed the number of stalls we placed into operation in all of 2021" but that's just progress. They don't say the heavy phase is done. They talk about "we are entering the rollout of the federal government's NEVI program" - that's future. They talk about "we have been busy preparing" but not completed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.